No Data
No Data
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity
Stoke Therapeutics Price Target Cut to $20.00/Share From $21.00 by Canaccord Genuity
Stoke Therapeutics Is Maintained at Buy by Canaccord Genuity
Stoke Therapeutics Is Maintained at Buy by Canaccord Genuity
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Express News | HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
Jaguar8 : Oh wow
Jaguar8 : Good morning brother!
TrytosaveabitOP Jaguar8: Good morning my man!
TrytosaveabitOP Jaguar8: I was thinking it was going to be like 8/9 dollars! Hehehe
Jaguar8 : Only had 1.5hrs sleep
View more comments...